SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 195 filers reported holding SANGAMO THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.58 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $4,000 | -20.0% | 730 | 0.0% | 0.00% | -50.0% |
Q4 2021 | $5,000 | -28.6% | 730 | 0.0% | 0.00% | 0.0% |
Q3 2021 | $7,000 | -22.2% | 730 | 0.0% | 0.00% | -33.3% |
Q2 2021 | $9,000 | 0.0% | 730 | 0.0% | 0.00% | 0.0% |
Q1 2021 | $9,000 | -18.2% | 730 | 0.0% | 0.00% | -40.0% |
Q4 2020 | $11,000 | +83.3% | 730 | +12.3% | 0.01% | +66.7% |
Q3 2020 | $6,000 | 0.0% | 650 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $6,000 | -91.2% | 650 | -93.9% | 0.00% | -93.3% |
Q1 2020 | $68,000 | +1260.0% | 10,650 | +1538.5% | 0.04% | +1400.0% |
Q4 2019 | $5,000 | -16.7% | 650 | 0.0% | 0.00% | -25.0% |
Q3 2019 | $6,000 | -14.3% | 650 | 0.0% | 0.00% | 0.0% |
Q2 2019 | $7,000 | +16.7% | 650 | 0.0% | 0.00% | 0.0% |
Q1 2019 | $6,000 | -14.3% | 650 | 0.0% | 0.00% | -20.0% |
Q4 2018 | $7,000 | -22.2% | 650 | 0.0% | 0.01% | -16.7% |
Q3 2018 | $9,000 | 0.0% | 650 | 0.0% | 0.01% | -14.3% |
Q2 2018 | $9,000 | -25.0% | 650 | 0.0% | 0.01% | -22.2% |
Q1 2018 | $12,000 | – | 650 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Golden State Equity Partners | 154,360 | $897,000 | 0.45% |
Rhenman & Partners Asset Management AB | 761,429 | $4,424,000 | 0.44% |
Lombard Odier Asset Management (Switzerland) SA | 860,702 | $5,001,000 | 0.39% |
WASATCH ADVISORS LP | 10,576,997 | $61,452,000 | 0.30% |
Rokos Capital Management LLP | 977,663 | $5,861,000 | 0.27% |
KLK CAPITAL MANAGEMENT LLC | 44,323 | $258,000 | 0.26% |
Long Focus Capital Management, LLC | 340,000 | $1,975,000 | 0.25% |
Vanguard Capital Wealth Advisors | 33,380 | $193,000 | 0.14% |
Fort Sheridan Advisors LLC | 73,978 | $430,000 | 0.13% |
Delphia (USA) Inc. | 20,983 | $122,000 | 0.09% |